A Pathology-Associated Form of α-Synuclein
Phosphorylation of α-synuclein at serine 129 (pS129-α-syn) is strongly associated with pathological aggregation in synucleinopathies. A large proportion of α-syn present in Lewy bodies is phosphorylated at this residue, making pS129-α-syn a key molecular marker of disease-associated α-syn biology.
Sensitive measurement of pS129-α-syn across biofluids provides researchers with an important tool for investigating disease mechanisms and monitoring biomarker dynamics.
Ultra-Sensitive Detection with SPEAR UltraDetect™
The SPEAR UltraDetect™ pS129-α-syn assay delivers high analytical performance for quantitative biomarker measurement.
Key analytical features include:
-
Femtogram sensitivity with ~6 fg/mL LOD
-
High precision with average CV < 5%
-
5-log dynamic range enabling reliable quantification across healthy and disease samples
-
100% quantifiability in healthy samples across verified matrices
-
Verified performance in CSF, EDTA plasma, and serum
This combination of sensitivity and precision supports both cross-sectional comparisons and longitudinal monitoring of pS129-α-synuclein levels.
Minimal Sample Input. Maximum Performance.
The homogeneous, wash-free SPEAR UltraDetect™ workflow requires only 1 µL of diluted sample per replicate, preserving precious biofluid samples while enabling scalable biomarker studies.
The semi-automated workflow requires less than 30 minutes of hands-on setup, supporting high-throughput experiments and longitudinal research across large study cohorts.
Assay Specifications
EDTA Plasma
| MRD | 4X |
| Diluted Sample Volume | 1 µL |
| Raw Sample Volume to Machine | 10 µL |
| LOD (pg/mL) | 0.006 |
| fLLOQ (pg/mL) | 0.024 |
| Spike-recovery (% recovery) | 121% |
| Linearity (% recovery) | 88.5% |
| Intra-plate CV (AVG %) | 2.1% |
| Inter-plate CV (AVG %) | 8.1% |
| EDTA Plasma Quantifiability | 100% |
